Literature DB >> 22688252

Intravitreal expansile gas in the treatment of early macular hole: reappraisal.

Ta-Ching Chen1, Chang-Hao Yang, Chung-May Yang.   

Abstract

PURPOSE: To study the effects of intravitreal injection (IVI) of expansile gas for early macular holes (EMH).
METHODS: Prospective interventional case series. Twelve eyes of 12 patients with EMH (stage 2) underwent IVI of perfluoropropane 0.2 ml followed by 5 days' facedown positioning.
RESULTS: Six cases (50%) achieved vitreous-macula separation. Three cases (25%) had hole closure with vision improvement; one of them developed rhegmatogenous retinal detachment (RRD) and hole re-opening. Another case with persistent hole also developed RRD. Seven of the 9 cases without hole closure and the one where the hole re-opened had vitrectomy, all resulting in hole closure and vision improvement. Duration of symptoms had borderline significance for hole closure (p = 0.11) and subsequent visual improvement (p = 0.03).
CONCLUSION: With its low success rate, IVI of gas may not be a good option for EMH. Complications include retinal detachment. The procedure seems to not affect hole closure with subsequent vitrectomy.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22688252     DOI: 10.1159/000337840

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  3 in total

1.  It's a gas! Pneumatic release of VMT.

Authors:  T L Jackson; D H Steel
Journal:  Eye (Lond)       Date:  2016-11-04       Impact factor: 3.775

2.  Office-based intravitreal injection of expansile gas for management of macular hole in previously vitrectomized eyes.

Authors:  Michael A Apolinario; Shaun I R Lampen; Tien P Wong; Christopher R Henry; Charles C Wykoff
Journal:  Am J Ophthalmol Case Rep       Date:  2019-07-05

Review 3.  Optimal management of idiopathic macular holes.

Authors:  Haifa A Madi; Ibrahim Masri; David H Steel
Journal:  Clin Ophthalmol       Date:  2016-01-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.